Servier Ranked Among Top Companies Across Several Categories in 2024 PatientView Corporate Reputation of Pharma Survey
News
Servier Presentations at ASCO 2025 Reinforce Company Leadership in IDH-Mutated Cancers
Servier announces the appointment of Nitza Thomasson as Executive Director R&D Neurology
Servier Appoints David K. Lee to Executive Committee
Servier Announces Expansion of its Tibsovo (ivosidenib) Development Program Investigating its Safety and Efficacy in Patients Living with IDH1-Mutated Cancers in Both Hematological Malignancies and Solid Tumors
Servier Partners With Local Cancer Center to Support Research Graduate Students in the Boston Area
Servier to Present Data Across its Hematology Portfolio at the 2024 American Society of Hematology (ASH) Annual Meeting
Servier to Present Data on IDH-mutant Glioma at the 2024 Society for Neuro-Oncology (SNO) Congress
Servier’s VORANIGO® (vorasidenib) tablets receives FDA approval as first targeted therapy for Grade 2 IDH-mutant glioma